Cited by 34Virus-based gene therapy researchImmunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Viral gene delivery vectors: the next generation medicines for immune-related diseases

Open access
De Haan, Peter, Van Diemen, Ferdy R., Toscano, Miguel G.·2021·Human Vaccines & Immunotherapeutics

Abstract

Viruses have evolved to efficiently express their genes in host cells, which makes them ideally suited as gene delivery vectors for gene and immunotherapies. Replication competent (RC) viral vectors encoding foreign or self-proteins induce strong T-cell responses that can be used for the development of effective cancer treatments. Replication-defective (RD) viral vectors encoding self-proteins are non-immunogenic when introduced in a host naïve for the cognate virus. RD viral vectors can be used to develop gene replacement therapies for genetic disorders and tolerization therapies for autoimmune diseases and allergies. Degenerative/inflammatory diseases are associated with chronic inflammation and immune responses that damage the tissues involved. These diseases therefore strongly resemble autoimmune diseases. This review deals with the use of RC and RD viral vectors for unraveling the pathogenesis of immune-related diseases and their application to the development of the next generation prophylactics and therapeutics for todays' major diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21645515.2020.1757989

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • bioPROTACs would most likely be delivered as mRNA or DNA constructs via a viral vector gene delivery system or in a nanoparticle.

    “Indeed, bioPROTACs would most likely be delivered as mRNA or DNA constructs via a viral vector gene delivery system204–206 or in a nanoparticle207–209.”

    From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [204]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 65 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
De Haan, P., Van Diemen, F. R., & Toscano, M. G.
Affiliations
  • Department of R&D, Amarna Therapeutics B.V, Leiden, The Netherlands
  • Department of R&D, Amarna Therapeutics S.L, Sevilla, Spain
Corresponding author
Toscano, Miguel G.
Venue
Human Vaccines & Immunotherapeutics
Published
2020-05-15
Volume
17
Issue
1
Pages
14-21
ISSN
  • 2164-5515 (ISSN-L)
  • 2164-554X
OpenAlex
W3025156007
Cited by
34
References
65
Citations by year
2026: 2 · 2025: 13 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 5 · 2020: 1
FWCI
0.61
Type
journal article
Language
en
Open access
Locations
  • Human Vaccines & Immunotherapeutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Amarna Therapeutics B.V
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
cancer immunotherapy, T cell response, gene replacement therapy, genetic disorders, autoimmune disease, allergy, chronic inflammation, degenerative diseases, prophylactics
MeSH terms
Genes, Viral, Genetic Vectors, Viruses, Genetic Therapy, Gene Transfer Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review